References
1. Lioznov D.A., Dunaeva N.V., Chung N.H., Gorchakova O.V., Antonova T.V. Chronic hepatitis C: the current state of the problem. Nefrologiya [Nephrology]. 2019; 23 (4): 36–46. DOI: https://doi.org/10.24884/1561-6274-2019-23-4-36-46 (in Russian)
2. Konstantinov D.Yu., Konstantinova E.A., Sterbkova E.A., Popova L.L., Suzdal’tsev A.A. Individualization of antiviral treatment of chronic hepatitis. Eksperimental’naya i klinicheskaya gastoenterologiya [Experimental and Clinical Gastroenterology]. 2013; (6): 29–34. URL: https://cyberleninka.ru/article/n/individualizatsiya-protivovirusnogo-lecheniya-hronicheskogo-gepatita (in Russian)
3. Patlusov E.P., Ponezheva Zh.B., Mannanova I.V. The role of metabolic and immunological disorders in the progression of chronic hepatitis C. RMZh [Russian Medical Journal]. 2019; (10): 7–11. URL: http://www.rmj.ru/articles/infektsionnye_bolezni/Roly_metabolicheskih_i_immunologicheskih_narusheniy_v_progressirovanii_hronicheskogo_gepatita_S/#ixzz7lCNmw2l9 (in Russian)
4. Tamaki N., Kurosaki M., Higuchi M., et al. Genetic polymorphisms of IL28B and PNPLA3 are predictive for HCV related rapid fibrosis progression and identify patients who require urgent antiviral treatment with new regimens. PLoS One. 2015; 10 (9): e0137351. DOI: https://doi.org/10.3892/br.2021.1492
5. Baran B., Gulluoglu M., Soyer O.M., et al. Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C. J Viral Hepat. 2014; 21 (2): 111–20. DOI: https://doi.org/10.1111/jvh.12127
6. Moon C., Jung K.S., Kim D.Y., Baatarkhuu O., Park J.Y., Kim B.K., et al. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci. 2015; 60 (2): 573–81. DOI: https://doi.org/10.1007/s10620-014-3361-6
7. Muldashev E.R. Theoretical and applied aspects of the creation of allografts «Alloplant» for facial plastic surgery. Saint Petersburg, 1995: 136 p. (in Russian)
8. Muslimov S.A. Morphological foundations of the use of allogeneic biomaterials in regenerative surgery. Ufa, 2001: 237 p. (in Russian)
9. Chernousov A.F., Khorobrykh T.V., Karpova R.V. Regeneration of liver tissue under the influence of cryoprecipitate and alloplant. Khururgiya [Surgery]. 2015; (7): 27–33. DOI: https://doi.org/10.17116/hirurgia2015727-33 (in Russian)
10. Galimov O.V., Timerbulatov M.V., Garifullin B.M. Method of treatment of toxic hepatitis and cirrhosis of the liver. Patent of the Russian Federation No. 2205647. Byul. No. 16 dated 10.06.2003. (in Russian)
11. Nartaylakov M.A., Mingazov R.S., Mustafin A.H., Musharapov D.R., Sokolov V.P., Galimov I.I. Application of allogeneic biomaterials in surgery of diffuse and cystic liver diseases. Meditsinskiy vestnik Bashkortostana [Medical Bulletin of Bashkortostan]. 2007; 3–4: 25–35. (in Russian)
12. Aprelev A.E. Clinical and experimental substantiation and development of the pharmacopuncture method in the system of complex correction of myopia: abstract: Diss. Moscow, 2011: 23 p. (in Russian)
13. Kaybyshev V.T., Kil’debekova R.N., Sadykov F.A., et al. The effectiveness of dispersed biomaterial Alloplant in the complex therapy of duodenal ulcer. Meditsinskiy vestnik Bashkortostana [Medical Bulletin of Bashkortostan]. 2016: 6 (66): 15–8. URL: http://cyberleninka.ru/article/n/effektivnost-dispergirovannogo-biomateriala-alloplant-v-kompleksnoy-terapii-yazvennoy-bolezni-dvenadtsatiperstnoy-kishki (in Russian)
14. Mirkhaydarova Z.M., Grushina T.I. Clinical efficacy of classical acupuncture and pharmacopuncture with biomaterial «Alloplant» in the conservative treatment of exudative otitis media. Fizioterapeft [Physiotherapist]. 2016; (4): 4–10. URL: http://elibrary.ru/item.asp?id=26630956 (in Russian)
15. Mirkhaydarov R.Sh., Kil’debekova R.N., Urazbakhtin R.K. Medico-economic efficiency of the use of dispersed biomaterial «Alloplant» in the treatment of dorsopathies. Problemy standartizatsii v zdravookhranenii [Problems of Standardization in Health Care]. 2013; (1–2): 33–5. (in Russian)
16. Mirkhaydarov R.S. Method of treatment of viral hepatitis or cirrhosis of the liver with biomaterial «Alloplant». Patent of the Russian Federation No. 2609252 dated 11.11.2015. (in Russian)
17. Guidelines for the care and treatment of chronic infection caused by hepatitis C virus. Geneva: World Health Organization, 2019. License: CC BY-NC-SA 3.0 IGO. (in Russian)
18. Vinnitskaya E.V., Drozdov V.N., Yunusova Yu.M., et al. Diagnostic significance of serum markers of fibrosis in chronic liver diseases. Terapevticheskiy arkhiv [Therapeutic Archive]. 2013; 85 (2): 27–31. URL: https://cyberleninka.ru/article/n/diagnosticheskaya-znachimost-syvorotochnyh-markerov-fibroza-pri-hronicheskih-zabolevaniyah-pecheni (in Russian)
19. Calvaruso V., Dhillon A.P., Tsochatzis E., et al. Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation. J Gastroenterol Hepatol. 2012; 27: 1227–32. DOI: https://doi.org/10.1111/j.1440-1746.2012.07136
20. Navrotsky A.N. Diagnostic capabilities of methods for assessing liver fibrosis in chronic viral hepatitis. Terapevticheskiy arkhiv [Therapeutic Archive]. 2016; 88 (11): 149–55. DOI: https://doi.org/10.17116/terarkh20168811149-155 (in Russian)
21. Gomez-Dominguez E., Mendoza J., et al. Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Aliment Pharmacol Ther. 2008; 27: 441–7.
22. Baykova T.A., Lopatkina T.N. Diversity of extrahepatic manifestations of chronic viral hepatitis B and C, general principles of treatment. Therapeutic Archive. 2013; 85 (4): 106–10. URL: https://cyberleninka.ru/article/n/mnogoobrazie-vnepechenochnyh-proyavleniy-hronicheskih-virusnyh-gepatitov-v-i-s-obschie-printsipy-lecheniya (in Russian)
23. Gunyakova V.K. Mechanisms of apoptosis, its significance in the pathogenesis of viral hepatitis, possibilities of correction. Sibirskiy meditsinskiy zhurnal [Siberian Medical Journal]. 2005; (2): 5–13. (in Russian)